KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings' Current Deferred Revenue history spans 5 years, with the latest figure at $10.8 million for Q1 2023.

  • For Q1 2023, Current Deferred Revenue rose 4.3% year-over-year to $10.8 million; the TTM value through Mar 2023 reached $10.8 million, up 4.3%, while the annual FY2022 figure was $7.9 million, 15.01% up from the prior year.
  • Current Deferred Revenue for Q1 2023 was $10.8 million at GoodRx Holdings, up from $7.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $11.5 million in Q2 2022 and bottomed at $3.5 million in Q4 2019.
  • The 5-year median for Current Deferred Revenue is $8.5 million (2021), against an average of $8.5 million.
  • The largest annual shift saw Current Deferred Revenue surged 98.44% in 2020 before it grew 0.25% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.5 million in 2019, then soared by 98.44% to $6.9 million in 2020, then increased by 0.25% to $6.9 million in 2021, then increased by 15.01% to $7.9 million in 2022, then soared by 36.24% to $10.8 million in 2023.
  • Per Business Quant, the three most recent readings for GDRX's Current Deferred Revenue are $10.8 million (Q1 2023), $7.9 million (Q4 2022), and $11.0 million (Q3 2022).